Published in Healthcare Mergers, Acquisitions and Ventures Week, May 26th, 2007
Total product revenue was $59.8 million for the first quarter of 2007, a year-over-year increase of 43% compared to $41.9 million for the first quarter of 2006. MOVIPREP(R), OSMOPREP(TM) and VISICOL(R) combined, generated revenue of $11.0 million for the first quarter of 2007. Revenue from these three products, which comprise our bowel cleansing product line, contributed 18% of 1Q07 total product revenue. XIFAXAN(R) revenue for the first quarter of 2007 was $15.4 million, a 134% increase compared to the first quarter of 2006. COLAZAL(R)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.